<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675619</url>
  </required_header>
  <id_info>
    <org_study_id>5889</org_study_id>
    <nct_id>NCT04675619</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Pirfenidone in Progressive Chronic Hypersensitivity Pneumonitis</brief_title>
  <official_title>Evaluation of the Efficacy of Pirfenidone in Progressive Chronic Hypersensitivity Pneumonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy of pirfenidone in chronic hypersensitivity&#xD;
      pneumonitis. This study included 40 adult patients (≥ 18 years) with a diagnosis of chronic&#xD;
      progressive hypersensitivity pneumonitis. The included patients were divided into 2 groups 20&#xD;
      patients in each one.&#xD;
&#xD;
      Group 1: will receive pirfenidone in addition to the conventional treatment Group 2: will be&#xD;
      maintained on conventional treatment. Forced vital capacity (FVC),6 minutes walking&#xD;
      test(6MWT), oxygen tension in the arterial blood (PaO2), and St. George's Respiratory&#xD;
      Questionnaire (SGRQ ) were measured before and after 6 months of a pirfenidone treatment&#xD;
      trial.&#xD;
&#xD;
      Results&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale The present data about the treatment of CHP are few and largely based on&#xD;
      observational studies and expert opinion. It is suggested that pirfenidone may slow disease&#xD;
      progression in cases of CHP as it has some anti-inflammatory in addition to antifibrotic&#xD;
      effects.&#xD;
&#xD;
      Hypothesis Pirfenidone will slow disease progression in hypersensitivity pneumonitis patients&#xD;
&#xD;
      Research questions&#xD;
&#xD;
        1. Can pirfenidone slow disease progression in cases of CHP?&#xD;
&#xD;
        2. What about the safety of pirfenidone in cases of CHP?&#xD;
&#xD;
      This study aims to evaluate the efficacy of pirfenidone in chronic hypersensitivity&#xD;
      pneumonitis.&#xD;
&#xD;
      Objectives&#xD;
&#xD;
        1. To compare the functional and radiological parameters between patients group who receive&#xD;
           pirfenidone treatment and the patient group who receive conventional treatment: FVC, 6&#xD;
           minutes walking distance, the partial pressure of oxygen in arterial blood ( PaO2),&#xD;
           Pulmonary artery systolic pressure, St.George's Respiratory Questionnaire(SGRQ Score)&#xD;
           and Quantitative ILD score (QILD), by quantitative HRCT chest.&#xD;
&#xD;
        2. To compare the side effects between patients' group who receive pirfenidone treatment&#xD;
           and the patient group who receive placebo treatment&#xD;
&#xD;
      Study design An interventional randomized controlled study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration,. FVC is the most basic maneuver in spirometry tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 minutes walking distance</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>The 6-min walk test (6MWT) has gained importance in the assessment of functional exercise capacity in patients with chronic respiratory disease.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hypersensitivity Pneumonitis</condition>
  <arm_group>
    <arm_group_label>Oral pirfenidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pirfenidone will be administered orally in 267 mg capsules taken with food. The dose will be titrated over 2 weeks from one capsule three times a day during Week 1 to two capsules three times a day during Week 2 then maintenance dose (three capsules three times a day Week 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral pirfenidone</intervention_name>
    <description>Treatment</description>
    <arm_group_label>Oral pirfenidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Treatment</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 years old with a diagnosis of chronic progressive Hypersensitivity&#xD;
             pneumonitis:&#xD;
&#xD;
          -  &gt;10% extent of fibrosis (eg, reticulation) on high-resolution CT (HRCT) scan&#xD;
&#xD;
          -  Absolute decline in FVC% predicted &gt;5% within the previous 6 months despite&#xD;
             conventional treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding period&#xD;
&#xD;
          -  Patients with peptic ulcer, severe hepatic disease, severe kidney disease, severe&#xD;
             cardiac disease, and patients with other chronic pulmonary diseases.&#xD;
&#xD;
          -  Presence of active infection&#xD;
&#xD;
          -  History of alcohol or drugs abuse&#xD;
&#xD;
          -  Active smokers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eman Shebl</name>
      <address>
        <city>Zagazig</city>
        <zip>44555</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, Skowasch D, Park JS, Poonyagariyagorn HK, Wuyts W, Wells AU. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018 Dec 21;27(150). pii: 180076. doi: 10.1183/16000617.0076-2018. Print 2018 Dec 31. Review.</citation>
    <PMID>30578335</PMID>
  </reference>
  <reference>
    <citation>Li T, Guo L, Chen Z, Gu L, Sun F, Tan X, Chen S, Wang X, Ye S. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep. 2016 Sep 12;6:33226. doi: 10.1038/srep33226.</citation>
    <PMID>27615411</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Eman Shebl</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Alveolitis, Extrinsic Allergic</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

